輝瑞:接種第二劑疫苗約4至6個月後保護率降至84%
輝瑞(PFE.US)行政總裁Albert Bourla表示,在接種第二劑疫苗約4至6個月後保護率下降到約84%。
Bourla的言論是基於公司資助的研究結果所得,尚未經過同行的評審。該研究發現,在接種第二劑疫苗後的一週至兩個月內,疫苗的有效性達到96.2%,之後平均每兩個月下降6%。
Bourla表示,非常有信心加強針會將免疫反應提高到足以防止感染Delta型變種病毒的水平,公司計劃在8月中旬之前向美國監管機構正式提交有關加強針的數據。
不過美國疾病控制及預防中心(CDC)及美國食品及藥物管理局(FDA)曾發表聲明,認爲已經完全接種疫苗的美國人不需要注射加強針。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.